What We're Reading: Page 327
Industry reads hand-picked by our editors
Sep 23, 2016
Sep 22, 2016
-
Bloomberg
Juno spends big on R&D, production in CAR-T race to fight cancer
-
Stat
Secret trove reveals bold ‘crusade’ to make OxyContin a blockbuster
-
Reuters
UK okays Alexion drug costing up to $2 million but wants price cut
-
Wall Street Journal
Big Pharma's big checkbooks drive biotech resurgence
-
In the Pipeline
The Chan-Zuckerberg Initiative
Sep 21, 2016
-
BloombergGadfly
Allergan is making biotech expensive again
-
EP Vantage
Expect Glaxo to increase consumer focus as Walmsley takes driving seat
-
The Street
Cloudy outlook for Aerie Pharma's glaucoma drug
Sep 20, 2016
Sep 19, 2016
-
MIT Technology Review
17 and going blind: the high stakes of getting into a gene therapy trial
-
Bloomberg
'Holy Grail’ of oral insulin gives way to other tablets at Novo
-
Stat
New federal rules target woeful public reporting of clinical trial results
-
Forbes
Price increases to help drug hit $15 billion in sales
Sep 16, 2016
-
Bloomberg
Valeant heart drug discounts haven't materialized, hospitals say
-
The Street
Gilead's pipeline, maligned by investors, still packed with 4Q clinical trial readouts
-
New York Times
EpiPen maker Mylan quietly steers efforts to protect its price
-
Washington Post
Turmoil at federal agency threatens oversight of biomedical research
Previous
